We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Grants Merck’s Melanoma Drug Accelerated Approval

FDA Grants Merck’s Melanoma Drug Accelerated Approval

September 10, 2014

The FDA granted Merck’s new melanoma drug Keytruda accelerated approval and orphan drug status after a clinical trial indicated improved efficacy.

The approval status will allow doctors to prescribe Keytruda (pembrolizumab) to patients with advanced melanoma who’ve stopped responding to other therapies while Merck conducts confirmatory clinical trials, the FDA said. Phase 2 and 3 clinical studies are currently ongoing and Merck plans to make Keytruda available soon, the company said.

Although improvement in survival or symptoms has not yet been established, the FDA pointed to a clinical trial of 173 participants that showed roughly one in four patients had their tumors shrink. The effect lasted at least 1.4 to 8.5 months, and for most continued even after the trial ended at 8.5 months.

A separate safety trial of 411 participants with advanced melanoma showed side effects that included fatigue, cough, nausea, rash, constipation, joint pain and diarrhea, the FDA said. Keytruda also showed potential for severe immune-related side effects involving healthy organs such as the lung, colon and liver.

The FDA granted Keytruda priority review on the promise that it may represent a significant improvement over existing drugs. It’s the first therapy approved by the FDA to block the programmed death receptors (PD-1) cellular pathway that restricts the immune system’s ability to attack melanoma cells.

The Melanoma Research Foundation called the findings the most promising patient response seen so far in a treatment for the disease. Several other companies such as Bristol-Myers Squibb and AstraZeneca also are working on PD-1 treatments, foundation Executive Director Tim Turnham added.

Six drugs have been approved since 2011 to treat melanoma, FDA Office of Hematology and Oncology Products Director Richard Pazdur said. The therapies are a result of promising advances in treating the disease, he added, which is diagnosed in 76,100 Americans each year. — Bryan Koenig

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Drugs Submissions and Approvals

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 07Dec

      Proactive Supplier Management Using Quality Agreements

    • 13Dec

      FDA Inspection Overhaul: How Things Have Changed in 2023

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • T-cell Malignancy From CAR-T Cell Immunotherapies Gets FDA Investigation

    • Vivos Sleep Apnea Oral Device Gets FDA Nod While Philips Wrestles With Yet Another CPAP Safety Issue

    • Novo Nordisk Battles Wegovy/Ozempic Pretenders and Faces Mounjaro’s Superior Study Results

    • Social, Emotional Risks Associated With Multi-Cancer Screening Discussed by Adcomm

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing